Evaluating Different Immunotherapy Combinations
A platform clinical trial evaluates immunotherapy combinations with standard of care treatment for advanced pancreatic cancer.
A platform clinical trial evaluates immunotherapy combinations with standard of care treatment for advanced pancreatic cancer.
Dr. Shubham Pant is focusing his research on effective treatments for the KRAS mutation, found in 90% of pancreatic cancers.
Dr. Conan Kinsey looks at the MEK pathway as way to make immunotherapy more effective for pancreatic cancer patients.
Ed O’Connor has been getting chemotherapy for his pancreatic cancer since 2016. His disease is stable and he has to decide whether to cut back on the chemotherapy.
Dr. Conan Kinsey outlines a clinical trial that has moved quickly from the lab to phase I, with a dual approach to delivering pancreatic cancer treatment.
Researchers are testing a drug combination that adds immunotherapy to standard drugs used to treat pancreatic cancer and an antimalarial drug.
When Dr. Steve Bigelsen was diagnosed with stage IV pancreatic cancer, chemosensitivity testing led him to treatments beyond standard of care.